1. Introduction {#sec1}
===============

In the last 20 years, stem cells have received ample attention from researchers in both human and veterinary medicine for their functional characteristics and therapeutic potential in different applications \[[@B1]--[@B4]\]. The number of animals previously treated in veterinary medicine provides a consequential basis for estimating the effectiveness of stem cell therapy in the treatment of different diseases \[[@B5], [@B6]\]. Nearly all types of animal tissues can be repaired or regenerated by the explicit action of stem cells \[[@B7]\], which exhibit high potential for propagation and differentiation \[[@B8]\]. Moreover, animal models are extensively used to examine the properties and promising potential of stem cells for reasonable application in human medicine in the future. Consequently, human and veterinary medicine are intertwined in the emerging field of stem cell research. Pioneering innovations in stem cell research have been accomplished by the collaboration of clinical and veterinary scientists.

For instance, adult stem cells isolated from various sources, mainly bone marrow- (BM-) and adipose tissue- (AT-) derived stem cells, have been widely used for the treatment of different animal diseases \[[@B9], [@B10]\]. As in human medicine, adult mesenchymal stem cells (MSCs) play an important role in veterinary medicine for the treatment of acute injury and chronic disorders. In brief, MSCs, also known as marrow stromal cells \[[@B11]\] or mesenchymal progenitor cells, are considered the most heavily utilized stem cells in the field of regenerative medicine and tissue engineering \[[@B12], [@B13]\] to overcome the complications and limitations of gene-based therapies. Currently, MSCs are used in clinical cell therapies and trials in many countries \[[@B14]\] for their *in vitro* expansion, notable multilineage differentiation potential \[[@B15], [@B16]\], capability to treat tissue injury \[[@B17], [@B18]\], viability after long-term storage by cryopreservation \[[@B19]\], support of hematopoietic stem cell (HSC) expansion as feeder cells \[[@B20]\], and immunomodulatory properties \[[@B21], [@B22]\]. These extensively applied cells were first depicted by Friedenstein et al. as a cell population analogous to fibroblasts \[[@B23]\]. They have the potential to differentiate into numerous cell types such as osteoblasts, adipocytes, cardiomyocytes, chondrocytes, hepatocytes, and brain cells \[[@B24]--[@B35]\]. These cells can be isolated from BM, AT, peripheral blood, skeletal muscle, connective tissue of the dermis, and Wharton\'s jelly (WJ) as well as umbilical cord blood (UCB) \[[@B30], [@B36]--[@B39]\].

Although BM represents an abundant source of MSCs \[[@B33], [@B40]\] in the field of tissue engineering and cell-based therapy, harvesting of cells is invasive with a stringent donor age requirement and increased donor site morbidity \[[@B41]--[@B46]\]. Therefore, UCB has been identified as an ideal alternative source in terms of ease of accessibility as well as reduced morbidity. UCB carries a large number of MSCs per volume, which are more flexible and pluripotent than bone marrow-derived mesenchymal stem cells (BM-MSCs) \[[@B38], [@B47]\]. Additionally, it has been proposed that umbilical cord blood-derived mesenchymal stem cells (UCB-MSCs) are not as mature as other stem cells and may not induce alloreactive responses that harmonize the immune system \[[@B32], [@B48], [@B49]\] and have the lower carcinogenic potential \[[@B50]\].

Nevertheless, although the presence of HSCs and their isolation from UCB are well established \[[@B51]--[@B54]\], the statistics concerning the existence of UCB-MSCs are contentious and require further evaluation. Earlier experiments to isolate UCB-MSCs from different species have either been aborted, have been time-consuming and onerous \[[@B55]--[@B57]\], or have been only 30--60% effective under suitable conditions \[[@B38], [@B39], [@B58]--[@B63]\].

UCB-MSCs can be isolated from different species such as human \[[@B37], [@B58], [@B59], [@B64]--[@B74]\], sheep \[[@B75], [@B76]\], equine \[[@B77]--[@B79]\], canine \[[@B80]--[@B84]\], and goat \[[@B85]\]. Human UCB-MSCs (hUCB-MSCs) are collected noninvasively at the time of delivery, whereas sheep UCB is collected intrusively by the surgical intrauterine approach \[[@B75], [@B76]\]. Equine UCB represents a noninvasively and nontraumatically retrieved source of stem cells, with potentially excellent cellular characteristics including proliferation capacity, immune tolerance, and differentiation potency \[[@B78]\]. It is reported that UCB from more than 100 mares and foals has been collected safely and efficaciously. The enrichment rate of MSCs from equine UCB is very high compared with that of other species \[[@B86]\].

Canine and feline are mainly considered companion animals rather than laboratory animals. Generally, pet owners prefer their pet (canine and feline) to be neutered (spayed or castrated) for the purpose of sterilization. After spay, canine UCB (cUCB) is impossible to collect, as the females lose their reproductive capability. In this view, cUCB raises the problem of limited availability. Yet, there are a few studies on the successful isolation and application of canine UCB-MSCs (cUCB-MSCs).

Even though UCB-MSCs are the latest tool and have already been commercialized for human medicine, the progress of UCB-MSC research in veterinary medicine is at a standstill. Therefore, veterinary medicine must overcome the major challenges of UCB-MSCs. We know that cUCB-MSCs have a great impact on veterinary medicine. Thus, cUCB-MSCs should be further explored to boost the supply thereof. In this respect, this is the first review that highlights the limitations of cUCB for the isolation of MSCs and suggests another significant source of MSCs in canine.

2. Umbilical Cord Blood and Mesenchymal Stem Cells {#sec2}
==================================================

The umbilical cord, also known as the navel-string or birth cord, is the channel between the growing placenta and fetus. In the course of prenatal development, the umbilical cord is a physiological and inherent part of the fetus. Typically, the umbilical cord consists of two arteries (the umbilical arteries) as well as one vein (the umbilical vein) buried in WJ, a gelatinous element composed largely of mucopolysaccharides. The two umbilical arteries transfer deoxygenated, nutrient-diminished blood away, whereas the umbilical vein carries oxygenated, nutrient-boosted blood to the fetus. The umbilical cord is covered by an epithelium obtained from the enveloping amnion.

UCB has been utilized as a rich and readily available alternative source of primitive and unspecialized stem cells since 1988 \[[@B87]\]. The blood remaining in the umbilical vein after birth is an abundant source of hematopoietic stem and progenitor cells. This criterion makes UCB an allogenic donor source that can be applied in a variety of hematologic, pediatric, genetic, oncologic, and immunologic disorders \[[@B53], [@B88]--[@B90]\]. Fresh UCB is also an auspicious source of non-HSCs such as MSCs, endothelial cells, and unrestricted somatic stem cells \[[@B30], [@B91]--[@B93]\]. Although several previously published articles reported the identification of MSCs in UCB \[[@B38], [@B39]\], some authors debated the existence of MSCs in UCB and declared that only HSCs are present therein \[[@B56], [@B94]\]. The origin of MSCs in UCB is unrecognized, but it is possible that the cells are discharged from the fetal liver or bone marrow into the fetal circulation \[[@B65]\]. Presently, the isolation of MSCs from UCB has a lower success rate compared with BM-MSCs (63% versus 100%) \[[@B67]\]. AT is another alternative source that can be accessed less invasively and repeatedly with an easy procedure, resulting in larger quantities of fresh MSCs \[[@B95]\].

3. Process of Article Selection {#sec3}
===============================

We utilized the search engines PubMed and Google Scholar to gather a list of publications and manuscripts detailing research, employment, or isolation of MSCs from human and animal subjects from February 2003 to June 2017. For a report to be included in this survey, it must have contained "Umbilical Cord Blood-derived Mesenchymal Stem Cells (UCB-MSCs)" in either the heading or the abstract. The keyword "Umbilical Cord Blood-derived Mesenchymal Stem Cells (UCB-MSCs)" combined with "human," "equine," "sheep," "goat," and "canine" was used to generate the list. We did not include any review articles in our survey. Highly relevant articles were initially determined by the heading and abstract, followed by a further examination to confirm whether the collection of UCB was from human or animal subjects. We accept that this search technique was not encyclopedic, as there are many more articles in journals that are not included in PubMed or Google Scholar. We evaluated the listed studies by different characteristics such as the weight of the species, final blood volume, and enrichment rate of MSCs.

For studies in which UCB-MSCs were isolated from humans, the key areas recognized were ethics (informed consent was obtained), route of delivery, UCB unit and volume, and MSC success rate. For studies in which UCB-MSCs were isolated from animals, the key areas noted were ethics (reporting of omission and approval of the study by the Animal Care and Use Committee), study design (distribution of groups and sample number and volume), route of delivery, and experimental animals (species, breed, and weight).

4. UCB-MSC Articles Entailing Human and Animal Sources {#sec4}
======================================================

The electronic search singled out 130 articles. A total of 20 articles based on human and animal sources of UCB-MSCs were considered based on the heading, abstract, and content (species, UCB unit and volume, and MSC success rate). Review articles, duplicates, and irrelevant papers were removed. In total, 55% (11/20) of articles reported human subjects, and 45% (9/20) of papers reported animal subjects, such as equine, sheep, goat, and canine ([Table 1](#tab1){ref-type="table"}). Nine articles regarding human subjects stated that UCB was collected with the informed consent of the mothers, while four studies detailing animal subjects received approval from an animal ethics committee ([Table 2](#tab2){ref-type="table"}).

5. Success Rate of MSC Isolation from UCB {#sec5}
=========================================

Some researchers successfully isolated 33.3%--60% of hUCB-MSCs under different cell culture conditions \[[@B69], [@B71]\]. Bieback et al. reported that a net volume of more than 33 mL of UCB and a mononucleated cell (MNC) count higher than 1 × 10^8^ are difficult to achieve for the isolation of UCB-MSCs from human subjects. However, they were capable of increasing the success rate from 29% to 63% \[[@B37]\]. Jin et al. reported the isolation of 50% of UCB-MSCs from 24 pregnant women \[[@B67]\]. When the blood volume exceeds 90 mL, 90% of MSCs from UCB can be isolated \[[@B66], [@B70]\]. Liu et al. stated that the efficacy of MSC isolation from UCB can reach 75% (*n* = 144) \[[@B72]\]. Sibov et al. and Johannes et al. demonstrated that more than 70 mL of UCB is required for the successful isolation of MSCs \[[@B70], [@B73]\]. On the other hand, Thomas et al. isolated equine UCB-MSCs from a volume of 42 mL at a 100% success rate with PrepaCyte-EQ (PEQ) medium. The same authors isolated MSCs with a success rate of 57% from a volume of 65--250 mL of equine UCB \[[@B77], [@B78]\]. Different authors have investigated the isolation of MSCs from UCB of goat and sheep ([Table 3](#tab3){ref-type="table"}) \[[@B76], [@B85]\].

Although Kang et al. and Jang et al. separately continued their experiments with cUCB-MSCs, they did not explicitly provide any information about the blood volume and number of canine subjects they used \[[@B80], [@B83]\]. Lim et al. successfully isolated MSCs from an exceedingly low UCB volume of 8 mL \[[@B84]\]. As the UCB volume of canine is insufficient to isolate MSCs, another author utilized the blood of canine fetus heart along with UCB \[[@B82]\] (Tables [4](#tab4){ref-type="table"} and [5](#tab5){ref-type="table"}).

6. MSCs in Human and Veterinary Medicine {#sec6}
========================================

The application of stem cells in cell-based therapies and tissue engineering is increasing to overcome the complications and hurdles of gene therapy. In both animals and human, stem cell implantation can serve as an advanced treatment for some incurable conditions such as bone fracture malignancies \[[@B96], [@B97]\], spinal cord injuries \[[@B98]\], and genetic disorders \[[@B99]\]. Tables [6](#tab6){ref-type="table"} and [7](#tab7){ref-type="table"} summarize the application of MSCs in the treatment of a wide range of diseases in preclinical studies of experimental animal models and veterinary clinical studies of animals with naturally occurring diseases. In human medicine, MSC products have already been developed and approved in South Korea. Cartistem® (Medipost), the world\'s first allogenic hUCB-MSC drug, has gained popularity in South Korea since January 2012 for the treatment of cartilage injury and osteoarthritis, and efforts are presently being made to broaden its indications for different target diseases. However, the isolation and characterization of stem cells obtained from numerous tissues and sources have led to highly detracting arguments regarding stem cell therapy \[[@B100]--[@B102]\].

Stem cell researchers worldwide are endeavoring to acquire the ideal or optimal autologous or allogenic MSCs, not only from human but also from equine, canine, and feline, to treat diseases such as musculoskeletal diseases, degenerative arthritis, atopic dermatitis, myocardial disease, chronic renal failure, and nerve damage \[[@B103]\]. Based on the concept of "One Health," new synergistic therapies such as stem cell therapies for human and veterinary medicine are in increasing demand and developed in collaboration---the time for focus on human and animal health is now \[[@B104]\].

7. Therapeutic Potential and Sources of MSCs {#sec7}
============================================

MSCs, specifically multipotent stem cells, have the capability to generate adipogenic, chondrogenic, osteogenic, and myogenic as well as endothelial cell lineages \[[@B14], [@B37]\]. Because of these possibilities, there has been an increased focus on the isolation of MSCs from different sources for transplantation and tissue engineering. MSCs have been isolated from diverse adult-derived sources such as BM, AT, lung, heart, peripheral blood, synovium skeletal muscle, dermis, and dental pulp as well as from fetal or neonatal tissues such as amniotic fluid and membrane, placenta, UCB, cord vein, WJ, and umbilical cord \[[@B59], [@B105]--[@B108]\]. BM is a bountiful source of MSCs; however, AT is a reliable source of MSCs with the best frequency, and UCB seems to be a remarkable alternative source that allows expansion for a greater number of MSCs \[[@B59], [@B64], [@B67]\].

8. UCB-MSCs from Human Sources {#sec8}
==============================

The frequency of MSCs in hUCB is a point of controversy among researchers \[[@B56], [@B57], [@B107]\]. This is attributed to the persistent difficulties in the isolation of UCB-MSCs. Most researchers have adopted suitable conditions from the literature to enrich the recovery of UCB-MSCs, including choosing full-term UCB units, storing for no more than 15 h, and obtaining an MNC count above 1 × 10^8^ as the selection criterion for UCB units \[[@B37]\]. While Rebelatto et al. declared that sample volume did not correlate with MSC isolation \[[@B62]\], others have suggested that sample volume (minimum 33 mL \[[@B37]\] or 45 mL \[[@B109]\]) is a critical parameter. The enrichment rate of MSCs has varied broadly from 10% to 60% \[[@B110]--[@B112]\]. Namely, of 644 UCB units were subjected to MSC isolation in diverse studies, only 167 successful outgrowths have been recorded (26% success rate) \[[@B38], [@B58]--[@B60], [@B62], [@B113]\]. A high enrichment rate of 90% MSCs was obtained when the UCB volume was more than 80 mL \[[@B66], [@B70]\].

Many groups have reported an isolation efficiency of 65% using numerous culture methods such as reduction of monocytes and lymphocytes from MNCs before cell seeding, development of cells under hypoxia, and the inclusion of cytokines, platelet lysate, or medium supplements \[[@B64], [@B66], [@B114], [@B115]\]. Other published studies accomplished isolation of MSCs from human UCB with up to 40--90% efficiency by adopting different parameters \[[@B20], [@B37], [@B65]--[@B67], [@B69], [@B72]\]. [Table 8](#tab8){ref-type="table"} represents the yield rate of UCB-MSCs isolated from human and animal sources fulfilling special criteria.

9. UCB-MSCs from Animal Sources {#sec9}
===============================

Successful isolation of MSCs (up to 100%) from equine UCB has been reported with the use of special culture media with a large volume of 42--250 mL \[[@B77], [@B78]\]. Although the isolation of MSCs from sheep and goat was successful, the researchers did not reveal any specific parameters that resulted in an effective number of MSCs \[[@B75], [@B76], [@B85]\]. Based on our literature survey, we have demonstrated that a large volume of UCB with some other special determinants is a principal factor to achieve high MSC yield. As the blood volume of cUCB is too low to yield an efficient number of MSCs, cUCB may be recognized as an unsuitable source of MSCs. Lim et al. worked with a 58 kg mongrel dog, which very rarely have more than 8 mL of UCB \[[@B84]\]. In two independent studies by Kang et al. and Jang et al., UCB from multiple dogs was collected to obtain the desired number of MSCs \[[@B80], [@B83]\]. As the amount of UCB from canine cannot produce a sufficient number of MSCs, another researcher collected blood from the canine fetal heart and successfully obtained MSCs \[[@B82]\], which creates an inconsistency and ethical problems in the pursuit of animal experiments. Our attempt to isolate MSCs from the umbilical cord ([Figure 1](#fig1){ref-type="fig"}) \[[@B116]\] of three healthy dogs resulted in an average sample volume of 1 mL and a yield rate of 66% (unpublished data).

10. UCB from Companion Animals {#sec10}
==============================

Nowadays, canine cesarean sections (C-sections) are decreasing because of the increase in spaying or castration to prevent the birth of unwanted litters, extend longevity and promote pet health, and possibly mitigate undesirable behaviors. More precisely, spaying can help prevent uterine infections and breast tumors. Concurrently, castration of male companion animals precludes testicular cancer as well as some prostate problems. The traditional time for neutering is before the onset of sexual maturity, as long as the animal is healthy. Spaying involves abdominal surgery to remove the ovaries and uterus, whereas castration involves elimination of the testes, resulting in infertility. Under these circumstances, while acquiring cUCB is normally challenging, these removed reproductive organs are frequently accessible in veterinary clinics. Specifically, the ovaries and testes are often discarded as medical waste but are proven to be potent and reliable sources of MSCs. MSCs from these reproductive organs (testis and ovary with adjacent portions) with high differentiation potentiality have already gained popularity.

These MSCs are able to differentiate into three mesodermal cell types, including adipogenic, osteogenic, and chondrogenic, indicating multipotent properties resembling those of AT-MSCs \[[@B117]\]. We can thoroughly examine the presence of MSCs in canine reproductive organs and surrounding tissues (fat and connective tissue) discarded during neutering operations; these MSCs also exhibit growth characteristics indistinguishable from those of AT-MSCs. Therefore, further investigation of canine reproductive organs and tissues with the assistance of new preservation technology \[[@B118]\] will improve our understanding of reproductive stem cell biology to potentially augment cell-based therapies and regenerative medicine.

Unlike in humans, it is almost impossible to obtain UCB from canine immediately after natural birth, as the dam\'s instinct prompts her to ingest the puppy\'s placenta and umbilical cord. From this perspective, we have made many efforts (unpublished data) to collect cUCB from Korean veterinary clinics. However, this was difficult, as many pet owners tend to prevent their pet from breeding. Conversely, if the canine pet is pregnant, the owner generally prefers natural birth unless a medical reason necessitates C-section. Therefore, the reduction in canine C-sections in veterinary hospitals, the introduction of specialized breeders, and changes in the supply of canine make it almost impossible to obtain UCB from canine. Conducting a surgical procedure or C-section in canine solely to obtain UCB for laboratory purposes gives rise to the question of legitimacy. To solve this problem, we can use MSCs from canine AT \[[@B95]\] along with reproductive tissue. It has been demonstrated that MSCs from AT have higher frequency and potentiality compared with UCB-MSCs \[[@B59], [@B67]\].

11. Conclusions {#sec11}
===============

One challenge in cellular therapy and regenerative medicine is the availability of alternative stem cell sources. Although cUCB-MSCs can proliferate and differentiate as stem cells, cUCB is not an ideal source because of low volume and ethical considerations of using a companion animal. In this regard, we suggest broadening the investigation of canine reproductive tissue and AT, instead of UCB, as the preferred source of MSCs.
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###### 

Articles included in this survey regarding UCB-MSCs from different species.

  Sources of UCB   Reference                                                    Number of articles
  ---------------- ------------------------------------------------------------ --------------------
  Human            \[[@B20], [@B37], [@B58], [@B65]--[@B67], [@B69]--[@B73]\]   11
  Animal           \[[@B75]--[@B78], [@B80], [@B82]--[@B85]\]                   9

###### 

Summary of ethical approval in studies that reported the collection of UCB from human and animal subjects.

  Ethics                                  Reference                                                            
  --------------------------------------- -------------------------------------------------------------------- ------------------------------------
  Informed consent from UCB donors        \[[@B20], [@B37], [@B58], [@B65]--[@B67], [@B69], [@B70], [@B73]\]   \[[@B71], [@B72]\]
  Approval from animal ethics committee   \[[@B75], [@B80], [@B84], [@B85]\]                                   \[[@B76]--[@B78], [@B82], [@B83]\]

###### 

Summary of papers that reported data regarding the isolation of UCB-MSCs from human, equine, sheep, and goat.

  Species   Breed        Route of delivery                UCB unit   UCB volume (mL)   Frequency of MSCs (%)   Reference
  --------- ------------ -------------------------------- ---------- ----------------- ----------------------- --------------------
  Human     ---          Vaginal                          10         50                60                      \[[@B71]\]
  Human     ---          Cesarean                         35         ---               40                      \[[@B69]\]
  Human     ---          Vaginal                          13         60                46                      \[[@B20]\]
  Human     ---          Vaginal                          59         108               63                      \[[@B37]\]
  Human     ---          Vaginal                          24         ---               50                      \[[@B67]\]
  Human     ---          Vaginal                          ---        ≥80               90                      \[[@B66], [@B70]\]
  Human                  Cesarean                         456        ≥90               90.9                    \[[@B65]\]
  Human     ---          Vaginal                          144        ---               75                      \[[@B72]\]
  Human     ---          Vaginal                          9205       40--321           ---                     \[[@B73]\]
  Human     ---          Vaginal                          30         ---               35                      \[[@B58]\]
  Equine    ---          Vaginal                          7          65--250           57                      \[[@B78]\]
  Equine    ---          Vaginal                          5          42                100                     \[[@B77]\]
  Goat      Mongrel      Vaginal                          ---        ---               ---                     \[[@B85]\]
  Sheep     Santa Ines   Surgical procedure               5          100               ---                     \[[@B76]\]
  Sheep     ---          Surgical intrauterine approach   4          10                ---                     \[[@B75]\]

###### 

Summary of papers that reported data regarding the isolation of MSCs from cUCB.

  Source of MSCs                         Breed     Weight (kg)   Route of delivery   UCB Unit   UCB Volume (mL)   Reference
  -------------------------------------- --------- ------------- ------------------- ---------- ----------------- ------------
  cUCB                                   Mongrel   58            C-section           1          8                 \[[@B84]\]
  cUCB and blood of canine fetus heart   ---       ---           ---                 ---        ---               \[[@B82]\]
  cUCB                                   ---       ---           C-section           ---        ---               \[[@B83]\]
  cUCB                                   Beagle    10.1          C-section           7          ---               \[[@B80]\]

C-section: Cesarean section.

###### 

Summary of purposes of cUCB studies.

  Purpose of experiment                                                                Reference
  ------------------------------------------------------------------------------------ ------------
  Transplantation of cUCB-MSCs in spinal cord injured dogs                             \[[@B84]\]
  Isolation and characterization of cUCB-MSCs                                          \[[@B82]\]
  Implantation of cUCB-MSCs mixed with *β*-TCP to enhance osteogenesis                 \[[@B83]\]
  Comparison of osteogenic potential of canine MSCs derived from AT, BM, UCB, and WJ   \[[@B80]\]

*β*-TCP: beta-tricalcium phosphate.

###### 

Preclinical studies with MSCs.

  Cell source   Cell type                     Pathology                                   Outcome                                                                  Reference
  ------------- ----------------------------- ------------------------------------------- ------------------------------------------------------------------------ ----------------------
  Rat           Human AD-MSC                  Peripheral nerve injury                     Repair of nerve                                                          \[[@B119]\]
  Rat           Human AD-MSC                  Cerebral ischemia                           Repair of nerve                                                          \[[@B120]\]
  Mouse         Human UCB-MSC                 Hind limb ischemia                          Repair of artery                                                         \[[@B121]\]
  Rat           Human UCB-MSC                 Cavernosal nerve injury                     Improved function                                                        \[[@B122]\]
  Rat           Allogenic AD-MSC              Peripheral nerve injury                     Repair of nerve                                                          \[[@B123]\]
  Rat           Allogenic BM-MSC              Skin wound                                  Repair of skin                                                           \[[@B124]\]
  Rat           Autologous BM-MSC             Spinal cord injury                          Repair of nerve                                                          \[[@B125]\]
  Rat           Autologous AD-MSC             Spinal cord injury                          Repair of nerve                                                          \[[@B126]\]
  Rat           Mouse SC-MSC                  Erectile dysfunction                        Improved function                                                        \[[@B127]\]
  Rabbit        Human AD-MSC                  Spinal cord injury                          Repair of nerve                                                          \[[@B128]\]
  Rabbit        Human UCWJ-MSC                Normal                                      No immune rejection                                                      \[[@B129]\]
  Rabbit        Porcine S-MSC                 Osteochondral defect                        Immune rejection                                                         \[[@B130]\]
  Rabbit        Allogenic S-MSC               Articular cartilage defect                  Repair of defect                                                         \[[@B131]\]
  Rabbit        Allogenic BM-MSC              Articular cartilage defect                  Repair of defect                                                         \[[@B132]\]
  Rabbit        Allogenic/autologous BM-MSC   Bone defect                                 Repair of defect                                                         \[[@B133]\]
  Porcine       Autologous BM-MSC             Articular cartilage defect                  Repair of defect                                                         \[[@B134]\]
  Porcine       Mouse BM-CMSC                 Vocal fold wound                            Repair of vocal fold                                                     \[[@B135]\]
  Porcine       Allogenic S-MSC               Articular cartilage defect                  Repair of defect                                                         \[[@B136]\]
  Canine        Allogenic BM-MSC              Bone defect                                 Repair of defect                                                         \[[@B137]\]
  Canine        Allogenic BM-MSC              Cardiac ischemia                            Improved function                                                        \[[@B138]\]
  Canine        Allogenic BM-MSC              Myocardial infarction                       Improved function                                                        \[[@B139]\]
  Canine        Allogenic BM-MSC              Skin wound                                  Repair of skin                                                           \[[@B140]\]
  Canine        Allogenic BM-MSC              Normal                                      Inflammation, tubular necrosis, mineralization, and fibrosis of kidney   \[[@B141]\]
  Canine        Allogenic AD-MSC              Spinal cord injury                          Repair of nerve                                                          \[[@B80]\]
  Canine        Allogenic UCB-MSC             Spinal cord injury                          Repair of nerve                                                          \[[@B84]\]
  Canine        Autologous BM-MSC             Disc degeneration                           Repair of nerve                                                          \[[@B142], [@B143]\]
  Canine        Autologous BM-MSC             Bone defect                                 Repair of defect                                                         \[[@B144]\]
  Canine        Autologous BM-MSC             Static nerve injury                         Repair of nerve                                                          \[[@B145]\]
  Canine        Autologous BM-MSC             Osteochondral defect                        Repair of defect                                                         \[[@B146]\]
  Canine        Autologous BM-MSC             Myocardial infarction                       Improved function                                                        \[[@B147]\]
  Canine        Autologous BM-MSC             Osteonecrosis of the femoral head           Repair of blood vessel                                                   \[[@B148]\]
  Canine        Autologous BM-MSC             Oral ulcer                                  Repair of ulcer                                                          \[[@B149]\]
  Canine        Autologous BM-MSC             Diabetes                                    Improved function                                                        \[[@B150]\]
  Canine        Autologous BM-MSC             Vocal fold wound                            Repair of vocal fold                                                     \[[@B151], [@B152]\]
  Canine        Autologous BM-MSC             Periodontal defect                          Repair of defect                                                         \[[@B153]\]
  Canine        Autologous BM-MSC             Periodontal class II furcation defect       Repair of defect                                                         \[[@B154]\]
  Canine        Allogenic/autologous BM-MSC   Spinal cord injury                          Repair of nerve                                                          \[[@B155]\]
  Canine        Autologous AD-MSC             Spinal cord injury                          Repair of nerve                                                          \[[@B156]\]
  Canine        Autologous MSC                Chondral defect                             Repair of defect                                                         \[[@B157]\]
  Canine        Allogenic AD-MSC              Thoracolumbar intervertebral disc disease   Improved clinical sign                                                   \[[@B158]\]
  Equine        Allogenic AD-MSC              Superficial digital flexor tendonitis       Repair of tendonitis                                                     \[[@B159]\]
  Equine        Autologous BM-MSC             Superficial digital flexor tendonitis       Repair of tendonitis                                                     \[[@B160]\]
  Equine        Autologous BM-MSC             Osteoarthritis                              Repair of osteoarthritis                                                 \[[@B161]\]
  Equine        Allogenic/autologous BM-MSC   Normal                                      Enhancement of MSC                                                       \[[@B162]\]
  Dolphin       Autologous AD-MSC             Normal                                      Cell collection success                                                  \[[@B163]\]
  Caprine       Autologous BM-MSC             Osteoarthritis                              Repair of osteoarthritis                                                 \[[@B164]\]

AT-MSC: adipose tissue-derived mesenchymal stem cells; UCB-MSC: umbilical cord blood-derived mesenchymal stem cells; BM-MSC: bone marrow-derived mesenchymal stem cells; SC-MSC: skeletal muscle-derived mesenchymal stem cells; S-MSC: synovium-derived mesenchymal stem cells; UCWJ-MSC: umbilical cord Wharton\'s jelly-derived mesenchymal stem cells.

###### 

Veterinary clinical studies with MSCs.

  Cell source   Cell type                  Pathology                                         Outcome                                                        Reference
  ------------- -------------------------- ------------------------------------------------- -------------------------------------------------------------- -------------
  Canine        Autologous BM-MSC          Gastrocnemius tendon injury                       Repair of tendon                                               \[[@B165]\]
  Canine        Autologous BM-MSC          Chronic Chagas cardiomyopathy                     Improved function                                              \[[@B166]\]
  Canine        Autologous AD-MSC          Chronic anconitis                                 Repair of anconitis                                            \[[@B95]\]
  Canine        Autologous AD-MSC          Arthritis, patella luxation                       Repair of arthritis                                            \[[@B167]\]
  Canine        Autologous AD-MSC          Chronic arthritis of hip joint                    Repair of arthritis                                            \[[@B168]\]
  Canine        Autologous AD-MSC          Atopic dermatitis                                 Repair of dermatitis                                           \[[@B169]\]
  Canine        Allogenic AD-MSC           Lumber herniated intervertebral disc              Repair of nerve                                                \[[@B170]\]
  Canine        Allogenic AD-MSC           Hip dysplasia                                     Improved function                                              \[[@B9]\]
  Canine        Autologous AD-MSC          Chronic osteoarthritis related to hip dysplasia   Reduced lameness                                               \[[@B171]\]
  Canine        Autologous AD-MSC          Severe osteoarthritis                             Reduced lameness                                               \[[@B172]\]
  Canine        Human ESC-MSC              Anal furunculosis                                 Recovery of fistulas                                           \[[@B173]\]
  Feline        Autologous AD-MSC          Chronic kidney disease                            Moderate improvement in GFR                                    \[[@B174]\]
  Feline        Allogenic AD-MSC           Chronic kidney disease                            Modest improvement in renal function                           \[[@B175]\]
  Feline        Allogenic AD-MSC           Chronic kidney disease                            No adverse effect                                              \[[@B176]\]
  Feline        Autologous AD-MSC          Chronic gingivostomatitis                         Reduction in the severity of clinical disease                  \[[@B177]\]
  Equine        Allogenic UCB-MSC          Chronic laminitis                                 Repair of laminitis                                            \[[@B178]\]
  Equine        Autologous BM-MSC          Tendon injury                                     Repair of tendon                                               \[[@B179]\]
  Equine        Autologous BM-MSC          Superficial digital flexor tendon                 Repair of tendon                                               \[[@B180]\]
  Equine        Autologous BM-MSC          Tendinitis, desmitis                              Repair of inflammation                                         \[[@B181]\]
  Equine        Autologous AD-MSC          Bone spavin                                       Improvement in inflammatory reaction and clinical conditions   \[[@B182]\]
  Equine        Allogenic AD-MSC           Endometriosis                                     Positive remodeling of endometrial tissue                      \[[@B183]\]
  Equine        Allogenic AD-MSC and PRP   Superficial digital flexor tendon                 Repair of tendonitis                                           \[[@B184]\]
  Equine        Allogenic AD-MSC and PRP   Tendonitis                                        Improved function                                              \[[@B185]\]
  Dolphin       Autologous AD/BM-MSC       Skin wound                                        Repair of skin                                                 \[[@B186]\]

AT-MSC: adipose tissue-derived mesenchymal stem cells; UCB-MSC: umbilical cord blood-derived mesenchymal stem cells; BM-MSC: bone marrow-derived mesenchymal stem cells; ESC-MSC: embryonic stem cell-derived mesenchymal stem cells; GFR: glomerular filtration rate; PRP: platelet-rich plasma.

###### 

Yield rate of UCB-MSC isolation from human and equine fulfilling special criteria.

  Source of UCB   Parameters                                                 Yield rate (%)   Reference    
  --------------- ---------------------------------------------------------- ---------------- ------------ ------------
  Human           Explant method                                             40               \[[@B69]\]   
  Human           Large BV with HPL medium                                   46               \[[@B20]\]   
  Human           Large number of UCB units                                  50               \[[@B67]\]   
  Human           Large BV with MesenCult Proliferation kit                  60               \[[@B71]\]   
  Human           ST ≤ 15 h, BV ≥ 33 mL, ≥10^8^ MNC count                    63               \[[@B37]\]   
  Human           Large number of UCB units with serum-free culture medium   75               \[[@B72]\]   
  Human           Factorial experiment with large BV                         ≥90              \[[@B66]\]   
  Human           ST ≤ 2 h, V ≥ 90                                           90.9             \[[@B65]\]   
  Human           DP ≤ 37 weeks, BV ≥ 80 mL, ST ≤ 6 h                        90               \[[@B70]\]   
  Equine          BV 42 mL                                                   PEQ medium       100          \[[@B77]\]
  FUD medium      60                                                                                       
  FD medium       20                                                                                       
  Equine          Large BV                                                   57               \[[@B78]\]   

HPL: human platelet lysate; MNC: mononucleated cell; ST: storage time; BV: blood volume; DP: duration of pregnancy; PEQ: PrepaCyte®-EQ medium; FUD: Ficoll-Paque™ PREMIUM medium loaded with undiluted whole blood, FD: Ficoll-Paque PREMIUM medium loaded with diluted whole blood.
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